Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator

Coronary recanalization rates and changes in plasma proteins of the fibrinolytic system were evaluated with two preparations of recombinant tissue-type plasminogen activator (rt-PA): the early formulation in liquid excipient ("old" rt-PA) and the later lyophilized form ("new" rt-PA). The dose dependency of coronary recanalization and of effects on plasma proteins was evaluated for the new rt-PA. Four groups of patients were studied: Study 1, 80 mg old rt-PA infused intravenously over 3 hours (n = 113); Study A, 80 mg new rt-PA over 3 hours (n = 47); Study B, 100 mg new rt-PA over 3 hours (n = 83); and Study C, 150 mg new rt-PA over 6 hours (n = 62). With equal doses of 80 mg, coronary recanalization rates at 90 minutes of infusion, determined angiographically, averaged 62% (Study 1) and 45% (Study A) with no overlap of 95% confidence limits. Increasing the dose of the new rt-PA to 100 mg, recanalization rates at 90 minutes averaged 71% (Study B), similar to those observed in Study 1. An increase to 150 mg resulted in higher recanalization rates at 30 minutes of infusion, 42% compared with 24% in Study 1 with no overlap of 95% confidence limits, and comparable rates at 90 minutes, 76 versus 62%. A linear trend test indicated a significant relation (p less than 0.01) between the dose of the new rt-PA and the rate of coronary recanalization at 30, 60 and 90 minutes of infusion. The new rt-PA affected plasma proteins of the fibrinolytic system less than the old form. There was a dose-dependent relation (p less than 0.001) in the effect of the new rt-PA on the plasma proteins. The frequency of bleeding complications was similar in the four study groups. These results indicate that the new rt-PA is less potent than the old rt-PA, in relation to both coronary reperfusion and systemic fibrinogenolysis. A higher and longer dosage regimen caused more rapid recanalization with similar effects on fibrinogenolysis.

This article has been cited by other articles:

				A. Bruno, P. Trouillas, L. Derex, F. Philippeau, N. Nighoghossian, J. Honnorat, M. Hanss, P. French, P. Adeleine, and M. Dechavanne Predicting rtPA Associated ICH in Acute Stroke * Response: Stroke, December 1, 2004; 35(12): 2762 - 2763. [Full Text] [PDF]

				P. Trouillas, L. Derex, F. Philippeau, N. Nighoghossian, J. Honnorat, M. Hanss, P. Ffrench, P. Adeleine, and M. Dechavanne Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis: A Study of 157 Cases Stroke, June 1, 2004; 35(6): 1323 - 1328. [Abstract] [Full Text] [PDF]

				C. Hooke Recombinant Tissue Plasminogen Activator for Central Venous Access Device Occlusion Journal of Pediatric Oncology Nursing, July 1, 2000; 17(3): 174 - 178. [Abstract] [PDF]

				J. C. Chaloupka, D. C. Huddle, J. Alderman, S. Fink, R. Hammond, and H. V. Vinters A Reexamination of the Angiotoxicity of Superselective Injection of DMSO in the Swine Rete Embolization Model AJNR Am. J. Neuroradiol., March 1, 1999; 20(3): 401 - 410. [Abstract] [Full Text]

				C. P. Cannon, C. M. Gibson, C. H. McCabe, A. A. J. Adgey, M. J. Schweiger, R. F. Sequeira, G. Grollier, R. P. Giugliano, M. Frey, H. S. Mueller, et al. TNK Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction : Results of the TIMI 10B Trial Circulation, December 22, 1998; 98(25): 2805 - 2814. [Abstract] [Full Text] [PDF]

				R. L White Thrombolytic Therapy in Acute Myocardial Infarction Part II: 1997 Update Asian Cardiovasc Thorac Ann, March 1, 1998; 6(1): 03 - 10. [Abstract] [Full Text] [PDF]

				C. P. Cannon, C. H. McCabe, C. M. Gibson, M. Ghali, R. F. Sequeira, G. R. McKendall, J. Breed, N. B. Modi, N. L. Fox, R. P. Tracy, et al. TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A Dose-Ranging Trial Circulation, January 21, 1997; 95(2): 351 - 356. [Abstract] [Full Text]

				S. Anand and S. L. Diamond Computer Simulation of Systemic Circulation and Clot Lysis Dynamics During Thrombolytic Therapy That Accounts for Inner Clot Transport and Reaction Circulation, August 15, 1996; 94(4): 763 - 774. [Abstract] [Full Text]

				L. Chouhan, H. A. Hajar, T. George, and J. C. Pomposiello Clinical and Angiographic Features of Patients with an Occluded Versus a Patent Infarct Vessel After Intravenous Streptokinase for Acute Myocardial Infarction Angiology, June 1, 1993; 44(6): 425 - 431. [Abstract] [PDF]

				E. G. Bovill, M. L. Terrin, D. C. Stump, A. D. Berke, M. Frederick, D. Collen, F. Feit, J. M. Gore, L. D. Hillis, C. T. Lambrew, et al. Hemorrhagic Events during Therapy with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin for Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial Ann Intern Med, August 15, 1991; 115(4): 256 - 265. [Abstract] [PDF]

				C. DeTrana and R. M. Hurwitz Painful Purpura: An Adverse Effect to a Thrombolysin Arch Dermatol, May 1, 1990; 126(5): 690 - 691. [Abstract] [PDF]

				P. Sternberg Jr, H. E. Aguilar, C. Drews, and T. M. Aaberg The Effect of Tissue Plasminogen Activator on Retinal Bleeding Arch Ophthalmol, May 1, 1990; 108(5): 720 - 722. [Abstract] [PDF]

				D. Collen Coronary Thrombolysis: Streptokinase or Recombinant Tissue-Type Plasminogen Activator? Ann Intern Med, April 1, 1990; 112(7): 529 - 538. [Abstract] [PDF]

				D. W. Krichbaum and D. A. Trivedi Thrombolytic Therapy in Acute Myocardial Infarction Journal of Pharmacy Practice, January 1, 1990; 3(5): 332 - 348. [PDF]

				C. S. Kase, A. M. O'Neal, M. Fisher, G. N. Girgis, and J. I. Ordia Intracranial Hemorrhage after Use of Tissue Plasminogen Activator for Coronary Thrombolysis Ann Intern Med, January 1, 1990; 112(1): 17 - 21. [Abstract] [PDF]

				E. J. Harris JR and J. M. Porter Thrombolytic Therapy and Modern Vascular Surgery: An Overview Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1989; 2(2): 40 - 63. [PDF]

				P. R. Kowey, L. Fisher, E.-G. Giardina, C. V. Leier, D. T. Lowenthal, F. H. Messerli, and C. M. Pratt The TPA Controversy and the Drug Approval Process: The View of the Cardiovascular and Renal Drugs Advisory Committee JAMA, October 21, 1988; 260(15): 2250 - 2252. [Abstract] [PDF]